Navigation Links
ESTEVE Communicates its R&D Through a New Interactive Platform

BARCELONA, July 12, 2012 /PRNewswire/ --

This site is part of the  corporate web portal

  • ESTEVE's new website provides consise and updated information on its projects under development. Among these is the S1RA (Sigma-1 Receptor Antagonist), a new chemical entity, presently in Clinical Phase II, for treating several types of pain
  • In addition to defining the Company's main lines of research, this new website also discloses the Company's different and innovative models of collaboration

ESTEVE announces the launch of a new website ( with the purpose of communicating the Company's R&D and the innovative models of collaboration currently implemented. Newly formatted and fully integrated in the web portal, this site reinforces the commitment of ESTEVE to R&D with emphasis on a solid strategy to provide new therapeutic solutions for unmet medical needs in highly prevalent diseases of high social impact.

With its primary focus in analgesia, ESTEVE is developing innovative therapies for pain. Two projects are presently undergoing clinical development for the treatment of neuropathic pain and moderate to severe acute and chronic pain.

One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist that offers a new approach and a new mechanism of action in a field (neuropathic pain) strongly in need of novel, more effective and safer therapies.

The new website also describes the innovative partnering strategy in R&D as well as ESTEVE's network of excellence built through unique collaborative models. This network includes different types of alliances, from public-private partnerships -such as the HIVACAT program to develop an effective vaccine against HIV and the Sanfilippo project to develop a treatment for a rare childhood disease- to R&D consortiums such as Neogenius for pain research.

One of the key features of this site is its attractively designed interface for portfolio presentation, which includes the various ongoing R&D programs, i.e. in-house projects in analgesia, projects in collaboration with other centers or companies, and in-licensed projects.

With language and information customized for each audience, this new website provides specific information for scientists, healthcare providers, industry partners, patients and other stakeholders.


ESTEVE is a leading chemical-pharmaceutical group in Spain and has a strong international presence. Ever since its foundation in 1929, ESTEVE has been firmly committed to excellence and has been using its best efforts to promote health and improve people's quality of life.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
2. picoSpin-45 Miniature NMR Spectrometer Wins R&D 100 Award
3. ORNL wins 9 R&D 100s, bringing total to 173
4. New life sciences R&D model based on real-time learning and data-sharing needed to sustain innovation
5. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
8. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
9. Nanodiamonds cut through dirt to bring back bling to low-temperature laundry
10. Soundbites Breaks Through at 47th AES Conference
11. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
Breaking Biology Technology:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):